GSK561679

DRUG5 trials

Sponsors

GlaxoSmithKline, Emory University, National Institute on Alcohol Abuse and Alcoholism (NIAAA), VA Office of Research and Development

Conditions

Alcohol DependenceDepressive Disorder and Anxiety DisordersDepressive Disorder, MajorStress Disorders, Post-TraumaticStress Disorders, Post-traumatic

Phase 1

To Investigate Effects GSK561679 on Part of the Body's System That Controls the Balance of Many of the Hormones.

CompletedNCT00426608

GlaxoSmithKlineDepressive Disorder and Anxiety Disorders

Start: 2006-10-06End: 2007-01-08Updated: 2017-09-11

Phase 2

A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder

CompletedNCT00733980

GlaxoSmithKlineDepressive Disorder, Major

Start: 2008-10-02End: 2010-06-18Updated: 2017-11-17

Evaluation of GSK561679 in Women With Post-Traumatic Stress Disorder

CompletedNCT01018992

Emory UniversityStress Disorders, Post-Traumatic

Start: 2009-12-31End: 2014-08-31Updated: 2017-03-07

CRF1 Antagonist GSK561679 in Alcoholism

CompletedNCT01187511

National Institute on Alcohol Abuse and Alcoholism (NIAAA)Alcohol Dependence

Start: 2010-01-31End: 2015-09-30Updated: 2016-11-07

Analyzing Female Trauma Exposed Responses to a Medication

CompletedNCT01814332

VA Office of Research and DevelopmentStress Disorders, Post-traumatic

Start: 2010-01-01End: 2014-10-31Updated: 2021-06-25

Related Papers

DNA methylation levels are associated with CRF1 receptor antagonist treatment outcome in women with post-traumatic stress disorder

Clinical Epigenetics2018-11-0343 citations

Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial.

2014-06-2132 citations